Abstract：
The objective of this study was to evaluate the efficacy of various dosing regimens of omadacycline against main drug-resistant pathogens in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Monte Carlo simulations were conducted using pharmacokinetic parameters and pharmacodynamic data to calculate cumulative fractions of response (CFRs) in terms of drug area under the concentration curve/minimum inhibition concentration targets.CFR ≥ 90% was considered optimal for a dosage regimen. CFR of any approved oral/intravenous regimen with loading-dose was ≥ 90% against methicillin-resistant Staphylococcus aureus (MRSA) for ABSSSI and penicillin-resistant Streptococcus pneumonia, tetracycline-resistant Streptococcus pneumonia, MRSA and β-lactamase positive Haemophilus influenzae for CABP. In conclusion, approved oral/intravenous loading and maintenance doses of omadacycline showed enough efficacy in the treatment of ABSSI and CABP caused by the main drug-resistant pathogens.
摘要：
这项研究的目的是评估奥马环素的各种给药方案对主要耐药病原体在治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）和社区获得性细菌性肺炎（CABP）中的疗效。使用药代动力学参数和药效学数据进行蒙特卡罗模拟,以根据浓度曲线下的药物面积/最小抑制浓度目标计算累积响应分数(CFR)。CFR≥90%被认为是剂量方案的最佳方案。任何批准的口服/静脉给药方案对ABSSSI和青霉素耐药链球菌肺炎的耐甲氧西林金黄色葡萄球菌（MRSA）的CFR≥90％，耐四环素肺炎链球菌,MRSA和β-内酰胺酶阳性流感嗜血杆菌用于CABP。总之,批准的口服/静脉负荷和维持剂量的奥马环素在治疗由主要耐药病原体引起的ABSSI和CABP方面显示出足够的疗效。
